Esophageal Cancer
Conditions
Keywords
esophageal cancer, postoperative radiotherapy, adjuvant radiotherapy
Brief summary
This retrospective study is exploring the treatment effect and toxicity of adjuvant radiotherapy in patients diagnosed with esophageal squamous cell carcinoma after R0 resection.
Detailed description
Surgery is one of the most important curative approaches for esophageal cancer. In real-world clinical practice, over 50% of the patients receiving surgical resection as primary management. For patients treated with surgical resection without adjuvant therapy, the probability of local-regional recurrence ranged from 23.0% to 56.5%, accounting for 55.6%-84.5% of the disease recurrence. Once encountering disease recurrence, the subsequent prognosis could be dismal. The median survival time after postoperative disease recurrence ranged from 3 to 8 months. Postoperative radiotherapy (PORT) was one of the potential topical treatment approaches prolonging local-regional recurrence time or moreover, attaining superior disease-free survival (DFS) or overall survival (OS) in selected patients. It is essential to identify patients potentially benefit from PORT. Besides, there were few studies evaluating the impact of postoperative radiation dose to survival outcomes in patients receiving PORT. Whether the PORT-related local-regional recurrence free survival (LRFS) enhancement could convert to OS or DFS improvement is still vague. The current study aimed at evaluating the value of PORT in patients diagnosed with esophageal squamous cell carcinoma after R0 resection.
Interventions
RADIATIONAdjuvant Radiotherapy
Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
Sponsors
Fujian Cancer Hospital
Chinese Academy of Medical Sciences
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* KPS≥70 * Pathologically diagnosis of esophageal cancer * Complete resection (R0 resection)
Exclusion criteria
* Diagnosed with other malignancy within 5 years before surgery * Encountered recurrence or port-site implantation receiving palliative-intended radiotherapy * Diagnosed with adenosquamous carcinoma or basal cell-like carcinoma * Treated with PORT with uncertain radiation dose * Treated with PORT with radiation dose \> 60Gy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | up to 5 years | From the date of surgery to the date of death or the most recent follow-up. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease-free survival (DFS) | up to 5 years | From the date of surgery to the date of any evidence of disease recurrence (recurrence in the tumor bed, anastomotic orifice, or in the regional lymph nodes, or metastasis in distant lymph nodes or distant organs), death or the most recent follow-up. |
| Local-regional recurrence-free survival (LRFS) | up to 5 years | From the date of surgery to the date of recurrence in the tumor bed, anastomotic orifice, regional lymph nodes or the most recent follow-up. |
| Distant metastasis (DM) | up to 5 years | From the date of surgery to the date of metastasis in distant lymph nodes, distant organs or the most recent follow-up. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | up to 5 years | From the date of surgery to the date of death or last follow-up |
Countries
China
Contacts
Primary ContactZefen Xiao, MD
Backup ContactWeiming Han, MD
Outcome results
None listed